FDA Peptide Reclassification 2026: What Researchers Want FDA Evaluates Peptides for Section 503A Compounding List Lance Liberti, MBA, BCPA posted on the topic LinkedIn Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # Regulatory Updates on Compounded Peptides New Drug Loft and VLS Pharmacy RFK Jr. may make it easier to get peptides what do doctors think? FDA Removes 12 Peptides from 503A Category 2 : r us_pharmacies